Evidence map›Paper›PMID 36864710›Full record

ArticleAmerican journal of medical genetics. Part C, Seminars in medical genetics2023

Gene-targeted therapies: Overview and implications.

P J Brooks, Tiina K Urv, Melissa A Parisi

Abstract read
In one paragraph

Article in American journal of medical genetics. Part C, Seminars in medical genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Landscape ofMolecular therapy. Methods & clinical development · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

P J BrooksNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-0567-6566
Tiina K UrvNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2040-4972
Melissa A ParisiEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-6707-1004

Funding

Intramural NIH HHS Z99 TR999999
6 · The paper itself

Abstract

Gene-targeted therapies (GTTs) are therapeutic platforms that are in principle applicable to large numbers of monogenic diseases. The rapid development and implementation of GTTs have profound implications for rare monogenic disease therapy development. This article provides a brief summary of the primary types of GTTs and a brief overview of the current state of the science. It also serves as a primer for the articles in this special issue.

Indexed as

Genetic TherapyHumans

Identifiers

PMID36864710
PMCPMC11331404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.